Archival ReportStriatal and Extrastriatal Dopamine D2/D3 Receptors in Schizophrenia Evaluated With [18F]fallypride Positron Emission Tomography
Section snippets
Subjects
Twenty-one patients and 22 matched healthy control subjects underwent a total of 43 [18F]fallypride scans (see Table 1 for clinical and demographic characteristics that include matching for age, gender, ethnicity, smoking status, and parental but not subject socioeconomic status [17]). Patients were medically healthy and met inclusion criteria for schizophrenia or schizoaffective disorder but no other DSM-IV (18) Axis I diagnosis; there was no substance abuse by history confirmed with negative
Results
Emission data were stable and continuous across the blocks of acquisition time in both patient and healthy control groups (Figure S1 in Supplement 1). Injected doses, masses, and specific activities of [18F]fallypride did not differ between the patient and healthy control groups (Table S1 in Supplement 1).
Discussion
We found baseline abnormalities in D2/D3 receptor binding in particular striatal and extrastriatal regions in this study. Increases in BP in thalamus and postcommissural caudate and a decrease in uncus were each detected with more than one outcome measure. Our finding in postcommissural caudate is consistent with prior literature showing a moderate increase in striatal D2/D3 receptor binding in schizophrenia (1, 36). The increase we found in thalamus does not replicate recent reports, and D2/D3
References (54)
- et al.
Fluorinated benzamide neuroleptics—IIIDevelopment of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F] fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer
Nucl Med Biol
(1995) - et al.
Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects
Biol Psychiatry
(2000) - et al.
Simplified reference tissue model for PET receptor studies
Neuroimage
(1996) - et al.
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1
Schizophr Res
(2008) - et al.
D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia
Schizophr Res
(2006) - et al.
Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender
Biol Psychiatry
(2006) - et al.
Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects
Biol Psychiatry
(2009) - et al.
Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain
Neurobiol Aging
(2000) - et al.
Age-related reduction of extrastriatal dopamine D2 receptor measured by PET
Life Sci
(2001) - et al.
Neurochemical and neuropharmacological imaging in schizophrenia
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects
Proc Natl Acad Sci U S A
Identification of extrastriatal dopamine D2 receptors in postmortem human brain with [125I]epidipride
Brain Res
Dopamine D2 receptors in the cerebral cortex: Distribution and pharmacological characterization with [3H]raclopride
Proc Natl Acad Sci U S A
Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesofrontal regions of human forebrain
Proc Natl Acad Sci U S A
Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain
Neuropsychopharmacology
Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex in human brain
J Pharmacol Exp Ther
Carbon-11-FLB 457: A radioligand for extrastriatal D2 dopamine receptors
J Nucl Med
In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman plrimates
Psychopharmacology (Berl)
Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia
Nature
Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects
Am J Psychiatry
Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, F-18-fallypride in nonhuman primates using positron emission tomography
Synapse
PET measurements of endogenous neurotransmitter activity using high and low affinity radiotracers
Neuroimage
Imaging human mesolimbic dopamine transmission with positron emission tomographyPart II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum
J Cereb Blood Flow Metab
Four Factor Index of Social Status
Diagnostic and Statistical Manual of Mental Disorders
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride
Neuropsychopharmacology
Performance evaluation of a whole-body PET scanner using the NEMA protocolNational Electrical Manufacturers Association
J Nucl Med
Cited by (67)
Medial Prefrontal Cortex Dysfunction Mediates Working Memory Deficits in Patients With Schizophrenia
2023, Biological Psychiatry Global Open ScienceThe substantia nigra in the pathology of schizophrenia: A review on post-mortem and molecular imaging findings
2023, European NeuropsychopharmacologySelectivity of probes for PET imaging of dopamine D3 receptors
2019, Neuroscience LettersPathway-Specific Dopamine Abnormalities in Schizophrenia
2017, Biological Psychiatry